Event snippet :
 
Search
  • Rory Quirkie

Aalto Bio Reagents Announces its SARS-CoV-2 Nucleocapsid Protein and...

Updated: May 11


Aalto Bio Reagents announces its Sars nCOV 2 Nucleocapsid protein and Monoclonals to NP are capable of detecting the conserved nucleoprotein Domain of Sars -cov-2 variants of interest including Omicron B.1.1.529.


Dublin, Ireland – December 13th 2021 – Aalto Bio Reagents Ltd. a leading developer of critical raw

materials and reagents for the development of diagnostic tests globally, announced today that its

Sars-CoV-2 n proteins CK6404 and monoclonals CA1360 which are part of numerous rapid assays

being run on the screening frontline in Europe and the U.S., are capable of detecting the conserved

nucleoprotein domain of Sars cov2 variants of interest including Omicron.


From the start of this COVID-19 pandemic in January 2019, Aalto Bio has supported over 50 global

diagnostic companies and vaccine developers with critical raw materials for use in building tests,

enabling frontline testing using multiples of millions of diagnostic tests. In February 2020 Aalto Bio

began offering its first nucleocapsid COVID-19 protein soon after the emergence of the Wuhan strain


of the virus. This was followed in April 2020 by COVID-19 lysis buffer reagent for pre-treating COVID-

19 samples prior to testing, together with monoclonals which were launched in late April. The early


availability of our COVID 19 proteins and Mabs has helped diagnostic manufacturers and vaccine

developers alike build high quality assays with our critical raw materials to faster determine the

clinical status of COVID-19.


“Aalto Bio Reagents Ltd. remain on hand to help our diagnostic manufacturing partners and vaccine

developers around the globe meet their COVID-19 diagnostic testing requirements. As new variants

emerge, we will continue to build critical materials as we have done since the outset of this world

health crisis and deliver first in class critical raw materials. We will continue to offer ourselves to

help innovate diagnostic testing to faster diagnose this virus“, stated Philip Noone CEO Aalto Bio.


About Aalto Bio Reagents

Founded in 1978, Aalto Bio Reagents is a leading developer and provider of raw materials to the in-

vitro diagnostics industry and research laboratories globally. We serve the largest multinational


companies in our industry with a broad range of purified human proteins; monoclonal and


polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; and disease state plasma for in-

vitro diagnostic application.


Since the company's inception, we have built strong working relationships with our clients who trust

us to provide them with the highest quality raw materials to meet the exacting standards of their

own product development requirements. Headquartered in Dublin, Ireland, the company is rapidly

expanding both its product portfolio and customer base. For further information please visit

http://www.aaltobioreagents.com


Click here to download press release


Contact Aalto Bio Reagents:


Tel: +353-1-4900685 | Email: info@aaltobioreagents.com




64 views0 comments